# A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

> **NCT06647745** · PHASE3 · RECRUITING · sponsor: **THPharm Corp.** · enrollment: 221 (estimated)

## Conditions studied

- Type 2 Diabetes
- Hypertension

## Interventions

- **DRUG:** THP-00101
- **DRUG:** THP-00102
- **DRUG:** THP-00103
- **DRUG:** THP-00104
- **DRUG:** THP-00105
- **DRUG:** THP-00106

## Key facts

- **NCT ID:** NCT06647745
- **Lead sponsor:** THPharm Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 221 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647745, "A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06647745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*